Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2003-01-21
2011-11-15
Haddad, Maher (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300
Reexamination Certificate
active
08058399
ABSTRACT:
A multispecific reagent has at least one first binding site for a cell surface receptor which requires multimeric ligand binding to be stimulated. The reagent possesses a second binding site for a target antigen which is expressed on the same cell as the cell surface receptor.
REFERENCES:
patent: 5891434 (1999-04-01), Krammer et al.
patent: 6010902 (2000-01-01), Ledbetter et al.
patent: 6042826 (2000-03-01), Caligiuri et al.
patent: 195 313849 (1997-02-01), None
patent: 0 336 379 (1989-11-01), None
patent: 2000-503672 (2000-03-01), None
patent: WO 94/20625 (1994-09-01), None
patent: WO 97/08205 (1997-03-01), None
patent: WO 97/12632 (1997-04-01), None
patent: WO 98/04592 (1998-02-01), None
patent: WO 99/48527 (1999-09-01), None
patent: WO 00/29431 (2000-05-01), None
Jung et al. Target Cell-restricted Triggering of the CD95 (APO-1/Fas) Death Receptor with Bispecific Antibody Fragments. Cancer Research 61, 1846-1848, Mar. 1, 2001.
Wahl et al. Improved radioimaging and tumor localization with monoclonal F(ab')2. J Nucl Med. Apr. 1983;24(4):316-325.
Herrmann et al. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res. Feb. 15, 2008;68(4):1221-7.
Jung et al. Monoclonal and Bispecific Antibodies as Novel Therapeutics. Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases, Ed. Los and Gibson, Springer, pp. 229-242, 2005.
Lens et al. A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. The Journal of Immunology, 156(2):507-514, 1996.
Coney et al. (1994) “Apoptotic cell death induced by a mouse-human anti-apo-1 chimeric antibody leads to tumor regression” Int. J. Cancer 58:562-567.
Jung et al. (1991) “Target cell-induced T cell activation with bi- and trispecific antibody fragments” Eur. J. Immunol. 21:2431-5 (Abstract Only).
Lexikon der Biologie/ Encyclopaedia of Biology 1999, pp. 323-329.
Roosnek et al. (1990) “T cell activation by a bispecific anti-CD3/anti-major histocompatibliity complex class I antibody” Eur. J. Immunol. 20:1393-6 (Abstract Only).
Segal et al. (1999) “Bispecific antibodies in cancer therapy” Current Opinion in Immunology 11:558-562.
Ogasawara, J. et al. (1993) “Lethal effect of the anti-Fas antibody in mice”Nature364:806-809.
Pfosser, A. et al. (1999) “Role of target antigen in bispecific-antibody-mediated killing of human gliobastoma cells: a pre-clinical study”Int. J. Cancer80:612-616.
Trauth, B. et al. (1989) “Monoclonal antibody-mediated tumor regression by induction of apoptosis”Science245:301-305.
Pitti, R.M. (1996) Induction of apoptosis by Apo-2 Ligand, a new member of the tumor necrosis factor cytokine familyJ. Biol. Chem.271:12687-12690.
Ashkenazi, a. et al. , Safety and Antitumor Activity of Recombinant Soluable Apo2 Ligand.The Journal of Clinical Investigation, 104:155-162, 1999.
Dhein, J. et al. 1992 Induction of Apoptosis by Monoclonal Antibody Anti-Apo-1 Class Switch Variants is Dependent on Cross-Linking of Apo-1 Cell Surface Antigens,The Journal of Immunology, 149:3166-3173.
Emmrich, F. et al. 1988 Selective Stimulation of Human T Lymphocyte Subsets by Heteroconjugates of Antibodies to the T Cell Receptor and to Subset—Specific Differentiation Antigens,European Journal of Immunology, 18:645-648.
Griffith, T. et al. 1999, Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies,The Journal of Immunology162:2597-2605.
Haddad Maher
Knobbe Martens Olson & Bear LLP
LandOfFree
Multispecific reagent for selectively stimulating cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multispecific reagent for selectively stimulating cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multispecific reagent for selectively stimulating cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4259711